Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.67 |
| ▸ | HTR2A | P28223 | 7/20 | 0.62 |
| ▸ | HTR2C | P28335 | 4/20 | 0.62 |
| ▸ | HTR1A | P08908 | 3/20 | 0.55 |
| ▸ | HTR2B | P41595 | 3/20 | 0.55 |
| ▸ | HTR1B | P28222 | 3/20 | 0.55 |
| ▸ | HTR1D | P28221 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | HTR1E | P28566 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1250301 | 1.00 | GPR84 (0.67) | GPR84HTR2AHTR2CHTR1AHTR2B | |
| SCHEMBL15265531 | 1.00 | GPR84 (0.67) | GPR84HTR2AHTR2CHTR1AHTR2B | |
| SCHEMBL16451189 | 0.89 | GPR84 (0.69) | GPR84HTR2AHTR2CHTR1AHTR2B | |
| SCHEMBL30776138 | 0.87 | HTR2A (0.69) | GPR84HTR2AHTR2CHTR1AHTR2B | |
| SCHEMBL22229850 | 0.87 | HTR2A (0.69) | GPR84HTR2AHTR2CHTR1AHTR2B | |
| SCHEMBL24912883 | 0.87 | HTR2A (0.69) | GPR84HTR2AHTR2CHTR1AHTR2B | |
| SCHEMBL30811413 | 0.87 | HTR2A (0.69) | GPR84HTR2AHTR2CHTR1AHTR2B | |
| SCHEMBL24690447 | 0.87 | HTR2A (0.69) | GPR84HTR2AHTR2CHTR1AHTR2B | |
| SCHEMBL29280816 | 0.87 | HTR2A (0.69) | GPR84HTR2AHTR2CHTR1AHTR2B | |
| SCHEMBL21944452 | 0.87 | GPR84 (0.65) | GPR84HTR2AHTR2CHTR1AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3578557-B1 | CHEMICAL PROCESS FOR PREPARING SPIROINDOLONES AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2023-09-20 | — | — | EP | disclosed |
| EP-3578557-B1 | CHEMICAL PROCESS FOR PREPARING SPIROINDOLONES AND INTERMEDIATES THEREOF | NOVARTIS AG (CH) | 2023-09-20 | — | — | EP | disclosed |
| US-20210348139-A1 | BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2021-11-11 | — | — | US | disclosed |
| US-20210348139-A1 | BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2021-11-11 | — | — | US | disclosed |
| US-20200123512-A1 | BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2020-04-23 | — | — | US | disclosed |
| US-20200123512-A1 | BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2020-04-23 | — | — | US | disclosed |
| US-10544402-B2 | Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs | CODEXIS INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-10544402-B2 | Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs | CODEXIS INC. (US) | 2020-01-28 | — | — | US | disclosed |
| EP-3578557-A1 | CHEMICAL PROCESS FOR PREPARING SPIROINDOLONES AND INTERMEDIATES THEREOF | Novartis AG (CH) | 2019-12-11 | — | — | EP | disclosed |
| EP-3578557-A1 | CHEMICAL PROCESS FOR PREPARING SPIROINDOLONES AND INTERMEDIATES THEREOF | Novartis AG (CH) | 2019-12-11 | — | — | EP | disclosed |
| US-20110275613-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-11-10 | — | — | US | disclosed |
| US-20110275613-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-11-10 | — | — | US | disclosed |
| US-8053442-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-8053442-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-8053442-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| CN-102015711-A | Spiro-indole derivatives for the treatment of parasitic diseases | NOVARTIS AG | 2011-04-13 | — | — | CN | disclosed |
| WO-2009132921-A1 | SPIRO-INDOLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2009-11-05 | — | — | WO | disclosed |
| US-20090275560-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-11-05 | — | — | US | disclosed |
| US-20090275560-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-11-05 | — | — | US | disclosed |
| US-20090275560-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275560-A1 | ORGANIC COMPOUNDS | OTC, PC, OAT | GPR84 3128/4885HTR2A 4638/4885HTR2C 4428/4885 |
| US-20110275613-A1 | ORGANIC COMPOUNDS | OTC, PC, OAT | GPR84 3092/4885HTR2A 4625/4885HTR2C 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.